GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-10-19| Partnerships

Illumina Teams Up With GenoScreen in Eradicating Tuberculosis

by Max Heirich
Share To

Illumina announced a partnership with genomics company GenoScreen for the acceleration of the World Health Organization’s (WHO) mission of eradicating Tuberculosis(TB). The goal of the partnership between the two firms is the expansion of detection and treatment in countries most affected by TB.

The partnership includes the distribution of products from both companies, with the WHO’s eradication end goal set for 2035.

Related Article: UNC Chapel Hill Research on Long Release Drugs for Fighting Tuberculosis

Eradicating Tuberculosis In Just Over A Decade

The WHO adopted the post-2015 End TB Strategy in 2014, aiming for the eradication of the disease throughout the world. Serving as a blueprint for countries, the strategy’s goal is the reduction of TB cases by 80% and TB death by 90%. 

Though most high-income countries do not see many cases, some still do occur there. However, a majority of cases take place in low to middle-income countries. About half of all cases pop up in the countries China, Bangladesh, India, Indonesia, Nigeria, Pakistan, Philippines, and South Africa. As a result of the COVID-19 pandemic, TB deaths saw an increase for the first time in decades. However, the pandemic also resulted in a larger rollout of Illumina’s NGS platform capacity, whose implementation the company intends to use in its efforts against TB. 

The partnership formed is centered around the rollout of Illumina’s sequencing products and GenoScreen’s Deeplex® Myc-TB assay. Deeplex is a sequencer with the ability to test, detect the genotype, and predict any potential antibiotic resistance. According to Illumina, Deeplex, in conjunction with Illumina’s own NGS sequencing platforms allows for “rapid determination of extensive drug resistance profiles and TB strain types affecting patients.”

On the announcement, André Tordeux, CEO of GenoScreen, said, “As a world specialist in TB genomic solutions, we envision this partnership with Illumina as an accelerator for the global deployment of our Deeplex Myc-TB assay, especially for countries with the highest needs.”

With Illumina and GenoScreen’s new partnership in support of the WHO’s initiative, the eradication of TB by 2035 seems like a more tangible possibility.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Roche’s STI Test Clears FDA Potentially Becoming A Game-Changer for Fast, Accurate Diagnosis
2025-01-23
Trump’s Move to Ditch the WHO Again: Day 1 Sees a Slew of Executive Orders Signed Off
2025-01-21
What is Tech Giant NVIDIA Doing Now? Latest Collabs Building the Healthcare Puzzle, One Byte at a Time
2025-01-15
LATEST
Novo Nordisk Bets Big on CagriSema With A Heavyweight Move Planned for 2026
2025-02-07
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease
2025-02-07
First-of-its-Kind Diagnostic Aid Uses a Single Hair Strand to Detect Autism Risk in Babies
2025-02-06
Teladoc Dials Up Virtual Care with $70 Million Acquisition of Catapult
2025-02-06
Silicon Valley in the Crosshairs as EU Readies to Strike U.S. Big Tech
2025-02-06
Johnson & Johnson Under Fire Again as Legal Action Over Alleged Talc-Cancer Link Moves to the UK
2025-02-05
MediBuddy Partners with Japan’s ELECOM to Launch Smart Health IoT Devices in India
2025-02-05
EVENT
2025-02-05
Precision Medicine World Conference 2025
Santa Clara, California
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top